Objective To test a novel methodology to define age-based dosing regimens for the treatment of malaria with a new, user-friendly, blister-packaged fixed-dose combination of artesunate and amodiaquine. Methods A weight-for-age reference database of 88 054 individuals from sub-Saharan Africa was compiled using data from Demographic Health Surveys, observational and intervention studies, and standardized for sex, age and malaria risk. We then determined the optimal tablet strength (milligram (mg) per tablet) and age-dose categories for the combination of artesunate and amodiaquine. The proportions of patients predicted to receive doses within newly defined therapeutic ranges for amodiaquine (7-15 mg/kg/day) and artesunate (2-10 mg/kg/day), were estimated for different age categories and mg tablet strengths using models based on the weight-for-age reference database. Findings The optimal paediatric (p) and adult (a) strength tablets contained 25/67.5 and 100/270 mg artesunate/amodiaquine, respectively. A regimen with five age categories: 0-1 months (½ p), 2-11 months (1 p), 1-5 years (2 p), 6-13 years (1 a), and > 14 years (2 a) had an overall dosing accuracy of 83.4% and 99.9% for amodiaquine and artesunate, respectively. Conclusion The proposed method to use weight-for-age reference data from countries where malaria is endemic is a useful tool for designing age-based dosing regimens for antimalarial drugs for drug registration and field use. Voir page 962 le résumé en français. En la página 962 figura un resumen en español.
Introduction
Rapid access to diagnosis and effective treatment is essential in the drive to roll back malaria. 1 Following the results of multicentre, proof of principle, clinic c cal trials of artesunate combined with standard antimalarials, WHO now recommends artemisinincbased comc c bination therapy (ACTs) as firstcline treatment for Plasmodium falciparum malaria. [2] [3] [4] [5] Four ACTs are currently recc c ommended: artesunate (AS) combined with mefloquine, amodiaquine (AQ) or sulfadoxine-pyrimethamine, and artec c mether-lumefantrine. Some 42 malaria endemic countries have now adopted or registered ACTs. 1 Practical, usercfriendly drug regic c mens should improve patient adherence, dosing accuracy, and, consequently, drug safety, effectiveness, and acceptability. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunateamodiaquine combination for treating falciparum malaria Walter .
‫صفحة‬ ‫يف‬ ‫بالعربية‬ ‫امللخص‬ ‫عىل‬ ‫االطالع‬ ‫ميكن‬
Usercfriendliness can be improved by blister packaging and the use of fixedc dose combination tablets. [7] [8] [9] [10] Fixedc dose combinations avoid the risk of singlecdrug intake, 11 ensure maximum parasiticidal effects and reduce the risk of the development of de novo resistant parasites. 12 Artemether-lumefantrine is currently the only internationally regc c istered, fixedcdose, artemisinincbased combination in use, but other fixedcdose combinations are being developed (e.g. AS plus amodiaquine, mefloquine, pyroc c naridine, chlorproguanil-dapsone, and dihydroartemisinin plus piperaquine).
In standard regulatory clinical tric c als for drug registration, drug doses are typically calculated according to body weight i.e. on a milligram per kilogram (mg per kg) basis. However, weightcbased dosing in countries where malaria is endemic is challenging because funcc c tioning weighing scales are scarce, access to formal health services is limited and most treatment occurs at home using antimalarials bought from shops and street vendors. [13] [14] [15] [16] Therefore, by default, the doses of most malaria treatments are administered by age. Cogniscent of this practice, WHO has produced both agec and weightcbased recommendations for the commonly used antimalarial drugs. 17 Agecbased dosing is more practical than weightcbased dosing, but inevitably results in some children receiving drug dosages, in mg per kg body weight, bec c low and above those recommended, with the attendant risks of treatment failure or toxicity.
Here, we report the use of a new methodology using weightcforcage referc c ence data from countries where malaria
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Anthropometric data to design age-based drug regimens Walter RJ Taylor et al. is endemic, to determine the optimal tablet strength (i.e. the amount of drug in mg per tablet) and corresponding agecbased dosing regimens for a new blistercpackaged fixedcdose combination of AS and AQ.
Methods
Our aim was to design a practical agec based dosing regimen that minimized the number of age categories and maximized the proportions of patients predicted to receive doses of AQ and AS within newly defined therapeutic ranges. We used computer models to compare the proportion of patients who were prec c dicted to receive dosages within the recc c ommended ranges with different tablet strengths of AQ and AS and different age categories using anthropometric referc c ence data from countries in subcSaharan Africa where malaria is endemic.
Definitions of adequate therapeutic dose margins
We defined therapeutic dose ranges for AS and AQ using current dosing recomc c mendations, published and unpublished data, and anecdotal clinical experience of their efficacy and tolerability. Dosing outside these limits was defined as either an underdose or overdose.
Amodiaquine
The 4caminoquinoline AQ is a well established antimalarial that is adminc c istered at doses of 25 or 30 mg/kg base over 3 days; 18, 19 WHO now recommends the higher dose. 2, 17, 20 The efficacy of AS and AQ depends on the degree of resistance to AQ. 2, 3 In Kenya a 28cday cure rate of only 68% was found, 2 but in southern Senegal, the efficacy of 3 days of treatment with cocblistered loose tablets of AS and AQ (Arsucam, Sanofi Aventis, France) was 95%. 21 The therapeutic range in Senegal was 7.5-15 mg/kg AQ per day (i.e. 22.5-45 mg/kg over 3 days).
As prophylaxis (400 mg weekly in adults), AQ has caused severe neutropec c nia (estimated risk 1/2000) and hepatitis (1/15650), both of which are potentially fatal. 22, 23 The main mechanism is probc c ably a type II hypersensitivity reaction to a quinone imine metabolite, but direct drug toxicity against bone marrow prec c cursors of white blood cells and hepatoc c cytes can not be excluded. [24] [25] [26] [27] When used as treatment, at a dosage according to weight or age, AQ alone or combined with AS is well tolerated. 28 The reported rates of drugcinduced vomiting, requiring a change of treatment (< 1.2%) and pruritus (< 1 to 2%), are low. 2, 21 Total AQ doses of 15-50 (median 31.3) mg/kg were well tolerated in 397 west Africans of all ages. 29 However, clinic c cal experience from Cameroon found vomiting to be troublesome in schoolc c children aged 5-15 years given an initial dose of 15 mg/kg of AQ. Consequently, this dose was replaced with 10 mg/kg with good results (P Ringwald, personal communication). Severe, asymptomatic neutropenia (< 1000/ml) was reported on day 28 in 9 of 152 (6%) children infected with P. falciparum when treated with AQ alone (total dose 30 mg/kg) or in combination with AS. 2 Based on these data, the therapeutic dose for AQ was set at 7.5-15 mg/kg/ day (i.e. 22.5-45 mg/kg over 3 days).
Artesunate
The currently recommended target dosc c age for AS is 4 mg/kg daily for 3 days. A dosecfinding study in Thailand found that 2 mg/kg/day of AS, when combined with mefloquine, was the lowest dose that achieved a maximum parasiticidal effect. 30 The currently recommended dose of 4 mg/kg/day takes into account the wide variation of AS concentrations between individual malaria patients, and so reduces the probability of underdosc c ing. 31 This dose of AS, combined with mefloquine, has achieved consistently high cure rates of more than 95% since 1995 on the western border of Thailand, an area with highly multidrug resistant P. falciparum. 32 As a class, the artemisinin comc c pounds are remarkably well tolerc c ated. 28, [33] [34] [35] [36] Serious, AScinduced toxicity is confined to acute anaphylaxis which has an estimated risk of 1 in 2833. [34] [35] [36] [37] Acute intravascular haemolysis has been described following treatment with AS, artemether and other antimalarials and is probably malariacrelated. 31, [38] [39] [40] The tolerability of AS in combination with other antimalarial drugs is essentially that of the partner drug. 3, 41 One study (n = 211) used a stat dose (a single dose given at one timecpoint) of 10 mg/kg of AS with mefloquine which was betc c ter tolerated than mefloquine alone; no adverse effects were associated with this dose of AS. 42 On the basis of these published data, the therapeutic dose for AS was defined as 2-10 mg/kg/day (i.e. 6-30 mg/kg over 3 days).
Weight-for-age reference population database
The WHO/National Centre for Health Statistics (WHO/NCHS) weightcforcage reference data are based on well nourc c ished populations from developed counc c tries and are appropriate for comparing the nutritional status of different populac c tions. 43 Our analysis required anthropoc c metric data from the target population itself. Therefore, a weightcforcage data set (n = 88 054) was created from individuc c als from countries in subcSaharan Africa where malaria is endemic. Reference data for African children < 5 years (y) of age from 21 countries were compiled from Demographic Health Surveys (DHS) with permission from the MeasurecDHS web site (http://www.measuredhs.com). 44 The remaining data (on children aged > 5 years) were provided by investigac c tors from six different nutritional surveys and other studies involving nutritional assessment in schoolchildren and adults
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Walter RJ Taylor et al. a To obtain the range in mg that needed to be tested we first obtained a crude estimate of the optimal tablet strength by multiplying the median weights for each age category by the currently recommended doses of 10 mg/kg/day for amodiaquine and 4 mg/kg/day for artesunate. This suggests that the optimal paediatric and adult tablet strengths for amodiaquine lay between 67 and 69 mg and between 260 and 290 mg base, respectively. Corresponding values for artesunate were between 26 and 29 mg and between 102 and 116 mg. Dosing accuracy was then compared for several candidate tablet strengths for amodiaquine ranging from 62.5 to 77.5 mg (with increments of 2.5 mg) for the paediatric strength tablet and 250 to 310 mg for the adult strength tablet (with increments of 10 mg). Corresponding candidates for the paediatric and adult tablet strengths for artesunate ranged from 20 to 35 mg (with 2.5 mg increments) and 80 to 140 mg, respectively (with increments of 10 mg). Dosing accuracy was defined as the proportion of individuals (using the MWAR data set) who were predicted to receive a dose within the therapeutic ranges when dose was based on age using the default age categories described above.
from Ghana, Kenya, Mozambique and the United Republic of Tanzania. This data set was standardized by age and sex, so that there was equal sex distribution in each 1cyear age category and the age distribution was typical of a subcSaharan African population, based on demographic tables published by WHO. 45 In this standardized data set, 29.5% of the children aged < 5 years were classified as underweight accordc c ing to the NCHS/WHO reference. The mean (standard deviation) weightcforc age Zcscore was -1.30 (0.59).
The analysis was also standardized (weighted) for malaria risk, taking into account that the risk of clinical malaria varies with age in subcSaharan Africa. We used a weighting factor of 3 for children aged 0-11 months, 4 for children 1-3 years, 3 for children 4-5 years, 2 for children 6-7 years and 1.5 for children 8-11 years relative to categories for older children and adults which were given a weighting factor of 1. The weighting facc c tors used were considered representative of the average age pattern for clinical malaria in malariacendemic countries in Africa. This final data set, i.e. standardc c ized for age, sex and malaria risk is rec c ferred to as the malariacweighted anthroc c pometric reference (MWAR) data set.
Determining the optimal tablet strength and age categories
We followed the convention of douc c bling the drug dose per age category and selected five age groups which had an approximate doubling in median bodyweight: 0-1 months (4.2 kg), 2-11 months (6.9 kg), 1-6 years (13.3 kg), 7-13 years (25.6 kg), and > 14 years (58.0 kg). Based on our predefined dosc c ing criteria (Table 1) , the corresponding doses were ½, 1, and 2 paediatric tabc c lets, and 1 and 2 adultcstrength tablets, respectively. These default age and dose groups were used to determine optimal tablet strengths.
The optimal tablet strengths defined in the initial model were subsequently used to see if dosing accuracy could be improved by using age categories different to the default categories described above.
Weight-for-age reference data in a healthy population versus malaria patients
The MWAR data from children < 5 years were compiled using DHS data obtained from random samples of predominantly healthy children as part of crosscsectional surveys. Few of these children would have had acute malaria at the time of the survey. To assess whether the use of the MWAR data set was appropriate for designing treatment regimens for sick children with acute malaria, we also defined the optimal regimen using a data set of 27 255 Mozambican chilc c dren aged < 5 years with clinical malaria who attended outpatient clinics (Alonso et al., unpublished data). The results were compared with those based on the MWAR data.
Dosing by body weight
To compare the performance of the agec based regimen with that of a weightc based regimen, the MWAR data set was used to determine optimal weight catc c egories based on the new tablet strengths and predefined dose categories.
Results

Optimal tablet strengths
The proportions of patients predicted to receive therapeutic doses for various tablet strengths of AQ and AS using the five default age categories are shown in Table 2 . The differences in these prec c dicted proportions of patients who will receive therapeutic doses, between AQ tablets containing between 67.5 and 75 mg (paediatric strength) and between 270 and 300 mg (adult strength) were negligible. Artesunate tablets containc c ing between 25 and 30 mg (paediatric strength) and between 100 and 120 mg (adult strength) would each result in 99.9 per cent of patients receiving doses within the range 2-10 mg/kg/day. We chose the tablets containing 67.5 and 270 mg of AQ and 25 and 100 mg of AS because they were associated with the lowest risk of overdosing.
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Optimal age categories
Subsequent models were run using the chosen tablet strengths (25/67.5 and 100/270 mg AS/AQ) with various age cutcoff points (Table 3 ; web version only, http://www.who.int/bulletin). This showed that for the step increase from 2 paediatric tablets to 1 adult tablet, an age cutcoff point of 6 rather than 7 years would improve the accuracy for AQ. All other optimal age cutcoff points were similar to the default cutcoff points used in the first model. For AS, dosing accuc c racy was very insensitive to changes in age cutcoff points, in contrast to that for AQ (Fig. 1) . Models run with 8 mg/kg as the upper cutcoff point for AS provided the same ageccut off points as the models that used 10 mg/kg as the upper threshc c old (data not shown).
With this new, optimal fiveccategory agecbased regimen, the overall proporc c tions of patients predicted to receive dosages within, below and above the therapeutic dose range were 83.4%, 7.4% and 9.1% for AQ, and 99.9%, 0.07% and < 0.01% for AS, respectively ( Table 4 ). The corresponding median doses were 10.2 mg/kg/day (AQ) and 3.6 mg/kg/day (AS).
Children aged 0-1 month, 12-23 months, 5-7 years and 13-15 years were at the highest risk of underdosing or overdosing with AQ (Table 3 ; web verc c sion only, http://www.who.int/bulletin and Fig. 1) . Compared with the fivec category agecbased regimen, a regimen with seven age categories (3 paediatric tablets for 5-7cyearcold children and 1½ adult tablets for 12-15cyearcold adoc c lescents) would improve overall dosing accuracy from 83.4% to 87.2% for AQ and from 99.90% to 99.97% for AS. Eight age categories (adding a 2½ adult tablets category for those > 18 years) would change these values to 89.4% and 99.8%, respectively.
Healthy reference population versus malaria patients
The proportions predicted to receive a dose within, below or above the therac c peutic range for AQ were 85.1%, 3.5% and 11.3%, respectively, with the Mozambique data set versus 81.6%, 3.6% and 14.8%, respectively, with the MWAR data set. The corresponding figures for AS were 99.99% within, 0.01% below and 0% above with the Mozambique data set versus 99.89%, 0.09 and 0.01%, respectively, with the MWAR data set.
Weight-based dosing
With five weight categories, 94.6% and 100% of patients would receive therac c peutic doses of AQ and AS, respectively (Table 5) .
Discussion
Using available weightcforcage referc c ence data from subcSaharan Africa, we determined the optimal tablet strength and agecbased dosing regimen for a new fixedcdose combination of AS plus AQ by modelling the proportions of patients receiving drug doses that are considered safe and efficacious.
Malaria control programmes need simple dosing regimens. Complicated regimens carry the risk of dosing errors, the effects of which may outweigh the intended advantages of greater accuracy. Therefore, we prioritized usercfriendliness, while considering carefully the ramificac c tions of this strategy in terms of safety and efficacy. We minimized the number of age categories and the use of tablet fractions by using paediatric and adult strength tablets with a milligram ratio Determining dosing accuracy dec c manded a redefinition of acceptable dosc c ing ranges for both drugs. The therapeuc c tic index was wide for AS (5cfold; 2-10 mg/kg/day), reflecting its excellent safety and tolerability. There was less flexibility with AQ (therapeutic index of 2; 7.5-15 mg/kg/day) because it has doseclimited toxicity (15 mg/kg/day), AQ had been reported to cause high rates of vomiting in children (P Ringwald, personal comc c munication). Thus, AQ determined the age cutcoff points for each age category. Because the upper limit for AS was based on a single study involving 220 patients from Thailand we also ran the models using a more conservative upper threshold of 8 mg/kg (therapeutic index 4). This did not change the definition of the optimal age cutcoff points of the combination, demonstrating again that the drug (AQ) with the lower therapeutic index determines the age categories. Nevertheless, an evaluation of the tolerability of this fixed AS/AQ combination will be necessary in further clinical trials and, when deployed widely, by pharmacovigilance.
The model predicted that virtually all patients in each age category would receive a therapeutic dose of AS with paec c diatric (25-30 mg) and adult (100-120 mg) tablet strengths. Tablets containing 25 and 100 mg AS were chosen because these carried the lowest risk of overdosc c ing; only 1 in 10 000 recipients would receive > 10 mg/kg/day; 1 in 250 would receive > 8 mg/kg/day; and 1 in 1000 patients < 2 mg/kg/day. The same reasonc c ing applied to the final choice of strength of the AQ tablets (67.5 and 270 mg), resulting in 83.4% of patients predicted to receive a therapeutic dose of AQ.
Two age categories were needed for infants because this is the period of maximum growth rate. Within each age-dosing category, younger and unc c derweight children are at greater risk of overdosing and vice versa. Models with seven or eight age-dosing categories would lead to a modest improvement in overall dosing accuracy (from 83.4% to 87.2% with seven categories and to 89.4% with eight categories) but a Total dose in mg divided by the median weight (50th percentile) and by the 1st and 99th percentile of the weight within a given age category of the standardized reference anthropometric data set from sub-Saharan Africa. b m = months; y = years. c p = paediatric tablet; a = adult tablet.
this would result in greater complexc c ity because tablet fractions, combining paediatric and adult tablets, and more blistercpack sizes would be required. The previous WHO guidelines recomc c mended eight dosing categories for AQ alone (153cmg tablets), with five age categories that require tablet fractions. 17 To our knowledge, adherence to this regimen has not been assessed, but is unlikely to be optimal. To improve dosc c ing accuracy further, dosing by weight is clearly preferable in settings where weighing scales are available, particularly for individuals with extreme weights for age ( Table 5) .
The anthropometric data for chilc c dren < 5 years were obtained from large DHS surveys. 44 Use of these household survey data has several important advanc c tages: the methodology is standardized, survey samples are large, nationally representative and available for most subcSaharan African countries. However, only a small proportion of these children will be acutely ill with malaria at the time of the survey. Malnourished children are more likely to develop clinical malaria, and malaria itself is associated with acute weight loss.
46-48 However, we showed
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Anthropometric data to design age-based drug regimens Walter RJ Taylor et al. that the differences between the weightc forcage distributions of children < 5 years of age with acute malaria seeking health care in Mozambique, and randomly selected children enrolled in DHS surc c veys were small; both data sets produced similar results. This suggests that DHS data are appropriate for defining malaria treatment regimens in young children.
DHS data were not available for older children and other adults. Analyses in these groups were based on much smaller numbers using anthropometric data from individual studies not specific c cally designed for this purpose. There remains a clear need for more reprec c sentative data on schoolcaged children, particularly those aged 5-7 years, and adults, to validate our observations in these older age groups. Furthermore, the dosing regimens presented here were based on African anthropometric a Total dose in mg divided by the median weight (50th percentile) and by the 1st and 99th percentile of the weight within a given weight category of the standardized reference anthropometric data set from sub-Saharan Africa. b The weight cut-off points for each weight category were determined by dividing the total amodiaquine dose given (No. of tablets × mg content of the amodiaquine tablet) by 15 mg/kg (the upper dose limit). For example, the lower weight limit for children receiving 1 paediatric tablet (67.5 mg) = (1 × 67.5)/ 15 = 4.5 kg, the lower weight limit of the next dosing group (2 paediatric tablets) = (2 × 67.5)/15 = 9 kg. The optimal lower and upper weight limits for children receiving 1 paediatric tablet are therefore 4.5 to < 9 kg. There were no preset criteria for the minimum weight in the lowest weight group or maximum weight in the highest weight group. Because of the narrower therapeutic index of amodiaquine, the weight categories for this drug were also used for artesunate. c p, paediatric tablet; a, adult strength tablet containing 270/100 mg amodiaquine/artesunate. data and may not be applicable to other countries. There is an urgent need for similar data sets from other regions where malaria is endemic. Our methodology does not take into account possible effects of body compositions (e.g. the ratio of lean body mass to body fat), age, gender or ethnicity on the pharmacokinetic and pharmacodynamic characteristics of AQ and AS. However, as with weightcbased dosing, it is an approximation of the complex relationship between these pac c rameters and drug safety and efficacy.
To the best of our knowledge, this is the first time modelling with stanc c dardized anthropometric reference data from countries where malaria is endemic has been used to define optimal tablet strengths and agecbased dosing regimens for treatment of the disease. 
Resumen
Uso del peso para la edad para optimizar la potencia de los comprimidos y la posología de una nueva combinación de dosis fijas de artesunato-amodiaquina para tratar la malaria por P. falciparum
Objetivo Ensayar una nueva metodología para definir los regímenes de dosificación basados en la edad para el tratamiento de la malaria con una nueva combinación de dosis fijas de artesunato y amodiaquina, fácil de usar y suministrada en forma de blísteres. Métodos Se compiló una base de datos de referencia del peso para la edad de 88 054 personas del África subsahariana a partir de datos de las Encuestas de Demografía y Salud y estudios observacionales y de intervención, que se normalizaron en función del sexo, la edad y el riesgo de malaria. A partir de ahí se determinó la potencia óptima de los comprimidos (milígramos (mg) por comprimido) y las categorías de edad-dosis para la combinación de artesunato y amodiaquina. Utilizando modelos basados en la base de datos de referencia del peso para la edad, se estimaron, para diferentes categorías de edad y potencias (mg) de los comprimidos, las proporciones de pacientes que recibirían dosis situadas dentro de los márgenes terapéuticos recién definidos para la amodiaquina (7-15 mg/kg/día) y el artesunato (2-10 mg/kg/día). Resultados La potencia óptima pediátrica (p) y para adultos (a) de los comprimidos fue de 25/67,5 y 100/270 mg de artesunato/ amodiaquina, respectivamente. Un régimen basado en cinco categorías de edad (0-1 meses (½ p), 2-11 meses (1 p), 1-5 años (2 p), 6-13 años (1 a), y > 14 años (2 a)) mostró una precisión de dosificación global del 83,4% y 99,9% para la amodiaquina y el artesunato, respectivamente. Conclusiones El método propuesto para usar datos de referencia del peso para la edad de los países con malaria endémica constituye una valiosa herramienta para diseñar regímenes de dosificación basados en la edad para los antimaláricos con miras al registro de medicamentos y a su uso sobre el terreno.
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